vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
USANA HEALTH SCIENCES INC is the larger business by last-quarter revenue ($250.2M vs $247.1M, roughly 1.0× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 3.0%, a 8.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -3.0%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 11.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
ANIP vs USNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $250.2M |
| Net Profit | $27.5M | $7.5M |
| Gross Margin | — | 76.2% |
| Operating Margin | 14.1% | 5.5% |
| Net Margin | 11.1% | 3.0% |
| Revenue YoY | 29.6% | -3.0% |
| Net Profit YoY | 367.5% | -20.0% |
| EPS (diluted) | $1.14 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $250.2M | ||
| Q4 25 | $247.1M | $226.2M | ||
| Q3 25 | $227.8M | $213.7M | ||
| Q2 25 | $211.4M | $235.8M | ||
| Q1 25 | $197.1M | $249.5M | ||
| Q4 24 | $190.6M | $213.6M | ||
| Q3 24 | $148.3M | $200.2M | ||
| Q2 24 | $138.0M | — |
| Q1 26 | — | $7.5M | ||
| Q4 25 | $27.5M | $180.0K | ||
| Q3 25 | $26.6M | $-6.5M | ||
| Q2 25 | $8.5M | $9.7M | ||
| Q1 25 | $15.7M | $9.4M | ||
| Q4 24 | $-10.3M | $4.5M | ||
| Q3 24 | $-24.2M | $10.6M | ||
| Q2 24 | $-2.3M | — |
| Q1 26 | — | 76.2% | ||
| Q4 25 | — | 78.2% | ||
| Q3 25 | — | 77.2% | ||
| Q2 25 | — | 78.7% | ||
| Q1 25 | — | 79.0% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | — |
| Q1 26 | — | 5.5% | ||
| Q4 25 | 14.1% | 1.7% | ||
| Q3 25 | 15.9% | 0.6% | ||
| Q2 25 | 6.6% | 7.1% | ||
| Q1 25 | 13.3% | 6.3% | ||
| Q4 24 | -2.3% | 3.8% | ||
| Q3 24 | -13.8% | 7.8% | ||
| Q2 24 | 3.7% | — |
| Q1 26 | — | 3.0% | ||
| Q4 25 | 11.1% | 0.1% | ||
| Q3 25 | 11.7% | -3.1% | ||
| Q2 25 | 4.0% | 4.1% | ||
| Q1 25 | 8.0% | 3.8% | ||
| Q4 24 | -5.4% | 2.1% | ||
| Q3 24 | -16.3% | 5.3% | ||
| Q2 24 | -1.7% | — |
| Q1 26 | — | $0.41 | ||
| Q4 25 | $1.14 | $-0.10 | ||
| Q3 25 | $1.13 | $-0.36 | ||
| Q2 25 | $0.36 | $0.52 | ||
| Q1 25 | $0.69 | $0.49 | ||
| Q4 24 | $-0.45 | $0.23 | ||
| Q3 24 | $-1.27 | $0.56 | ||
| Q2 24 | $-0.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $162.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | — |
| Total Assets | $1.4B | $739.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $162.8M | ||
| Q4 25 | $285.6M | $158.4M | ||
| Q3 25 | $262.6M | $145.3M | ||
| Q2 25 | $217.8M | $151.3M | ||
| Q1 25 | $149.8M | $179.6M | ||
| Q4 24 | $144.9M | $181.8M | ||
| Q3 24 | $145.0M | $364.9M | ||
| Q2 24 | $240.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $528.1M | ||
| Q2 25 | $436.8M | $531.1M | ||
| Q1 25 | $418.6M | $529.8M | ||
| Q4 24 | $403.7M | $532.1M | ||
| Q3 24 | $405.9M | $533.1M | ||
| Q2 24 | $455.8M | — |
| Q1 26 | — | $739.0M | ||
| Q4 25 | $1.4B | $742.9M | ||
| Q3 25 | $1.4B | $726.6M | ||
| Q2 25 | $1.3B | $734.5M | ||
| Q1 25 | $1.3B | $746.6M | ||
| Q4 24 | $1.3B | $748.2M | ||
| Q3 24 | $1.3B | $671.3M | ||
| Q2 24 | $920.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $-2.0M | ||
| Q2 25 | $75.8M | $12.2M | ||
| Q1 25 | $35.0M | $15.5M | ||
| Q4 24 | $15.9M | $5.8M | ||
| Q3 24 | $12.5M | $29.5M | ||
| Q2 24 | $17.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $-5.2M | ||
| Q2 25 | $71.8M | $7.2M | ||
| Q1 25 | $32.5M | $12.7M | ||
| Q4 24 | $13.5M | $4.0M | ||
| Q3 24 | $7.7M | $27.1M | ||
| Q2 24 | $13.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | -2.4% | ||
| Q2 25 | 34.0% | 3.0% | ||
| Q1 25 | 16.5% | 5.1% | ||
| Q4 24 | 7.1% | 1.9% | ||
| Q3 24 | 5.2% | 13.6% | ||
| Q2 24 | 9.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | 2.1% | ||
| Q1 25 | 1.3% | 1.1% | ||
| Q4 24 | 1.3% | 0.8% | ||
| Q3 24 | 3.2% | 1.2% | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 1.27× | ||
| Q1 25 | 2.23× | 1.65× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 2.78× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
USNA
Segment breakdown not available.
